Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$36.98

-0.92 (-2.43%)

, VRTX

Vertex

$182.33

-0.36 (-0.20%)

07:20
04/16/19
04/16
07:20
04/16/19
07:20

Crispr Therapeutics, Vertex announce fast track designation for CTX001 from FDA

Crispr Therapeutics (CRSP) and Vertex (VRTX) announced that the FDA has granted fast track designation for CTX001 for the treatment of transfusion-dependent beta thalassemia. CTX001 is an investigational, autologous, gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies.

CRSP

Crispr Therapeutics

$36.98

-0.92 (-2.43%)

VRTX

Vertex

$182.33

-0.36 (-0.20%)

  • 30

    Apr

  • 14

    May

CRSP Crispr Therapeutics
$36.98

-0.92 (-2.43%)

03/13/19
WBLR
03/13/19
INITIATION
WBLR
Market Perform
Crispr Therapeutics initiated with a Market Perform at William Blair
William Blair analyst Raju Prasad started Crispr Therapeutics with a Market Perform rating. The analyst views the company as the best pure-play on CRISPR technology, but cites competition and gene editing volatility for his neutral rating.
03/14/19
WBLR
03/14/19
INITIATION
WBLR
Market Perform
William Blair starts Crispr Therapeutics with Market Perform, $39 fair value
William Blair analyst Raju Prasad last night initiated coverage of Crispr Therapeutics with a Market Perform rating and $39 fair value estimate. The analyst acknowledges the innovative nature of the CRISPR/Cas9 discovery but views the most-progressed indications, targeted-beta-thalassemia and sickle cell with CTX001 and allogeneic T-cell therapy for hematological malignancies, as "hyper-competitive spaces where the company is behind the leaders in clinical development." As such, Crispr Therapeutics' current valuation adequately reflects the stage of clinical development for its product candidates, Prasad tells investors in a research note.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Piper Jaffray says Crispr Therapeutics remains a top pick for 2019
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $75 price target on Crispr Therapeutics, and added that Crispr remains a top pick for 2019, after the company announced the expansion of its wholly-owned allogeneic CAR-T pipeline at the American Association for Cancer Reseach, or AACR. Tenthoff said he expects more preclinical CAR-T data at the American Society of Gene and Cell Therapy, or ASGCT, in April. The analyst believes the biggest driver for the company remains "first-in-man Phase I/II CTX001 data in Beta-thal and potentially Sickle Cell Disease" this year.
04/11/19
EVER
04/11/19
INITIATION
Target $46
EVER
Outperform
Crispr Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Crispr Therapeutics with an Outperform rating and a price targets of $46. The analyst says the company's ex vivo gene therapy gives it a low risk path to market while it continues to refine its delivery systems required for in vivo editing. Mehrotra also cites Crispr's potential to have several programs in clinic in 2019-2020, along with strong partnerships and clinical execution that "could lead to significant near term clinical news flow."
VRTX Vertex
$182.33

-0.36 (-0.20%)

03/26/19
HCWC
03/26/19
NO CHANGE
Target $15
HCWC
Buy
Proteostasis regiments warrant further investigation, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein says it was his hope that the Proteostasis (PTI) compounds would generate a 10 ppFEV1 improvement and provide either a legitimate competitor for Vertex (VRTX) or identification of molecules that could serve as possible add-ons to other shelved or early development modulators. Factually, none of the dose cohorts measured at either seven-day or 14-days after treatment generated a 10 ppFEV1 improvement, Fein tells investors in a research note. However, due to the complete lack of any competition to the Vertex "strangle-hold" on the cystic fibrosis landscape as well as the "apparent if not overwhelming desire," at least outside of the U.S., for a second option, the Proteostasis regiments warrant further investigation, says the analyst. He believes yesterday's data may provide an opportunity in more severe cystic fibrosis patients. Fein keeps a Buy rating on Proteostasis with a $15 price target. The stock closed yesterday down 68%, or $2.76, to $1.31.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
03/26/19
03/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Strong Buy from Market Perform at Raymond James , to Hold from Sell at Loop Capital, and to Sector Weight from Underweight at KeyBanc. 2. BB&T (BBT) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying after meeting with CEO of SunTrust (STI), he remains positive on the merger and the combined stock. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at William Blair with analyst Y. Katherine Xu citing expectations that the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. 4. Allegiant Travel (ALGT) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio citing her meetings with its management last week. 5. TransAlta (TAC) upgraded to Buy from Hold at TD Securities with analyst John Mould saying Brookfield Renewable Partners (BEP) $750M investment in TransAlta improves the company's financial flexibility, accelerates its ability to return capital to shareholders and advance the coal-to-gas conversion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
EVER
04/11/19
INITIATION
Target $183
EVER
In Line
Vertex initiated with an In Line at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Vertex with an In-Line rating and a price target of $183. The analyst says the company has "great science, execution, and management", but its multiple is the highest relative to its peers and appears to be "priced to perfection". Mehrotra adds that the debate around EU pricing will intensify, becoming a "bigger and longer headwind".

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
04/24/19
04/24
12:16
04/24/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$8.35

-1.14 (-12.02%)

12:10
04/24/19
04/24
12:10
04/24/19
12:10
Downgrade
LG Display rating change  »

LG Display downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXY

Occidental Petroleum

$60.91

-1.44 (-2.31%)

, APC

Anadarko

$71.89

7.77 (12.12%)

12:09
04/24/19
04/24
12:09
04/24/19
12:09
On The Fly
Fly Intel: Wall Street's top stories at midday »

The major averages are…

OXY

Occidental Petroleum

$60.91

-1.44 (-2.31%)

APC

Anadarko

$71.89

7.77 (12.12%)

CVX

Chevron

$118.80

-3.2 (-2.62%)

BA

Boeing

$378.71

4.67 (1.25%)

T

AT&T

$30.75

-1.36 (-4.24%)

CAT

Caterpillar

$138.18

-3.9 (-2.74%)

CBS

CBS

$51.44

0.09 (0.18%)

VIA

Viacom

$36.81

0.53 (1.46%)

VIAB

Viacom

$29.88

0.61 (2.08%)

SAP

SAP

$127.96

13.12 (11.42%)

SLAB

Silicon Labs

$105.83

12.195 (13.02%)

EBAY

eBay

$38.25

1.59 (4.34%)

RES

RPC, Inc.

$11.10

-1.8 (-13.95%)

IRBT

iRobot

$103.20

-27.22 (-20.87%)

SNAP

Snap

$11.36

-0.63 (-5.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 26

    Apr

  • 26

    Apr

  • 29

    Apr

  • 30

    Apr

  • 02

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 10

    May

  • 10

    May

  • 14

    May

  • 14

    May

  • 18

    May

  • 20

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 24

    Jul

  • 13

    Nov

TDOC

Teladoc

$54.67

0.32 (0.59%)

, HUM

Humana

$249.01

0.71 (0.29%)

12:09
04/24/19
04/24
12:09
04/24/19
12:09
Recommendations
Teladoc, Humana analyst commentary at Baird »

Humana virtual primary…

TDOC

Teladoc

$54.67

0.32 (0.59%)

HUM

Humana

$249.01

0.71 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 22

    May

  • 23

    May

  • 05

    Jun

  • 13

    Nov

MPC

Marathon Petroleum

$60.06

-0.94 (-1.54%)

12:05
04/24/19
04/24
12:05
04/24/19
12:05
Options
Marathon Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 08

    May

UMC

UMC

$1.94

0.015 (0.78%)

12:04
04/24/19
04/24
12:04
04/24/19
12:04
Upgrade
UMC rating change  »

UMC upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

LRN

K12

$31.56

-4.665 (-12.88%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
K12 falls -12.4% »

K12 is down -12.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$4.28

-0.685 (-13.80%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
Superior Energy falls -13.9% »

Superior Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

RES

RPC, Inc.

$11.04

-1.86 (-14.42%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
RPC, Inc. falls -14.2% »

RPC, Inc. is down -14.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 08

    May

  • 09

    May

  • 13

    Nov

SAP

SAP

$128.22

13.38 (11.65%)

12:01
04/24/19
04/24
12:01
04/24/19
12:01
Hot Stocks
SAP rises 11.7% »

SAP is up 11.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 07

    May

APC

Anadarko

$71.92

7.8 (12.16%)

12:00
04/24/19
04/24
12:00
04/24/19
12:00
Hot Stocks
Anadarko rises 12.4% »

Anadarko is up 12.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 22

    May

TRK

Speedway Motorsports

$18.50

4.52 (32.33%)

12:00
04/24/19
04/24
12:00
04/24/19
12:00
Hot Stocks
Speedway Motorsports rises 32.8% »

Speedway Motorsports is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

12:00
04/24/19
04/24
12:00
04/24/19
12:00
General news
Treasury Action: Fed funds futures are rallying alongside the surge in Treasuries »

Treasury Action: Fed…

HMST

HomeStreet

$28.08

(0.00%)

11:50
04/24/19
04/24
11:50
04/24/19
11:50
Hot Stocks
HomeStreet 'disappointed' over Blue Lion's director nominations, proposals »

HomeStreet issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

PYPL

PayPal

$107.92

1.01 (0.94%)

, FB

Facebook

$183.84

0.07 (0.04%)

11:50
04/24/19
04/24
11:50
04/24/19
11:50
Earnings
Fly Intel: What to watch in PayPal earnings report »

PayPal (PYPL) is…

PYPL

PayPal

$107.92

1.01 (0.94%)

FB

Facebook

$183.84

0.07 (0.04%)

EBAY

eBay

$38.45

1.79 (4.88%)

JPM

JPMorgan

$113.45

-0.29 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 09

    May

  • 14

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 11

    Jun

  • 16

    Jul

AMRN

Amarin

$18.32

-0.07 (-0.38%)

11:45
04/24/19
04/24
11:45
04/24/19
11:45
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 06

    May

11:45
04/24/19
04/24
11:45
04/24/19
11:45
General news
Treasury's $20 B FRN auction was awarded at a high discount margin of 0.139% »

Treasury's $20 B FRN…

LRN

K12

$31.11

-5.115 (-14.12%)

11:40
04/24/19
04/24
11:40
04/24/19
11:40
Recommendations
K12 analyst commentary at Barrington »

Barrington reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$262.87

-0.98 (-0.37%)

, SSNLF

Samsung

$0.00

(0.00%)

11:40
04/24/19
04/24
11:40
04/24/19
11:40
Earnings
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

TSLA

Tesla

$262.87

-0.98 (-0.37%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

CAT

Caterpillar

$138.82

-3.26 (-2.29%)

11:37
04/24/19
04/24
11:37
04/24/19
11:37
Hot Stocks
Breaking Hot Stocks news story on Caterpillar »

Caterpillar: Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

GWW

Grainger

$292.75

-0.46 (-0.16%)

11:37
04/24/19
04/24
11:37
04/24/19
11:37
Hot Stocks
Grainger authorizes repurchase of additional 5M shares »

W.W. Grainger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BKU

BankUnited

$35.97

0.24 (0.67%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
Downgrade
BankUnited rating change at Sandler ONeill »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 15

    May

GWW

Grainger

$292.73

-0.48 (-0.16%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
Hot Stocks
Grainger raises dividend by 6% to $1.44 per share »

W.W. Grainger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BBY

Best Buy

$75.08

1.48 (2.01%)

, PG

Procter & Gamble

$104.47

1.28 (1.24%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
On The Fly
Best Buy, P&G, Snap upgrades among today's top analyst calls »

Check out today's top…

BBY

Best Buy

$75.08

1.48 (2.01%)

PG

Procter & Gamble

$104.47

1.28 (1.24%)

SNAP

Snap

$11.20

-0.79 (-6.59%)

KHC

Kraft Heinz

$32.73

-0.365 (-1.10%)

AAPL

Apple

$208.23

0.73 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 23

    May

  • 29

    May

  • 03

    Jun

TEVA

Teva

$14.98

0.07 (0.47%)

, MYL

Mylan

$26.47

-0.13 (-0.49%)

11:35
04/24/19
04/24
11:35
04/24/19
11:35
Recommendations
Teva, Mylan, Novartis analyst commentary at Wells Fargo »

Sandoz results should not…

TEVA

Teva

$14.98

0.07 (0.47%)

MYL

Mylan

$26.47

-0.13 (-0.49%)

NVS

Novartis

$78.35

2.51 (3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 08

    May

  • 22

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.